You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

radioligand therapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration-resistant Prostate Cancer Trial in Grand Rapids (SPECT/CT)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • SPECT/CT
  • Grand Rapids, Michigan
    BAMF Health
Apr 19, 2023

Prostate Cancer, Prostate Adenocarcinoma, Prostatic Tumors Trial in Montreal (131I-PSMA-1095 Radioligand Therapy (RLT))

Active, not recruiting
  • Prostate Cancer
  • +5 more
  • 131I-PSMA-1095 Radioligand Therapy (RLT)
  • Montreal, Quebec, Canada
    Stephan Probst
Oct 24, 2022

Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

Recruiting
  • Salivary Gland Cancer
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 27, 2022

Metastatic Castration-resistant Prostate Cancer (mCRPC) Trial (225Ac-PSMA-R2, 68Ga-PSMA-R2)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • (no location specified)
Aug 8, 2023

Mechanisms of Resistance to PSMA Radioligand Therapy

Recruiting
  • Prostate Cancer
  • Single-photon emission computed tomography
  • +2 more
  • Los Angeles, California
  • +2 more
Jun 22, 2022

Carcinoid Tumor Lung, Neuroendocrine Tumor of the Lung, Carcinoma, Small-Cell Lung Trial in Iowa City (212-Lead Pentixather,

Not yet recruiting
  • Carcinoid Tumor Lung
  • +2 more
  • 212-Lead Pentixather
  • 203-Lead Pentixather SPECT/CT
  • Iowa City, Iowa
    The University of Iowa Theranostics Center
Sep 23, 2022

177Lu-EB-FAPI Trial in Beijing (68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy)

Recruiting
  • 177Lu-EB-FAPI
  • 68Ga-FAPI for PET / CT scan and 177Lu-EB-FAPI for therapy
  • Beijing, Beijing, China
    Peking Union Medical College Hospital, Chinese Academy of Medica
May 27, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Image Guided Biopsy
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jun 17, 2022

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Atlanta (procedure, radiation, other, drug)

Not yet recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Biospecimen Collection
  • +6 more
  • Atlanta, Georgia
    Emory University Hospital/Winship Cancer Institute
Oct 25, 2023

Renal Cell Carcinoma Trial in Beijing (68Ga-PSMA, 1.85GBq (50 mCi) of 177Lu-EB-PSMA-617)

Recruiting
  • Renal Cell Carcinoma
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Dec 24, 2021

Prostate Cancer Trial in St Leonards, Perth (177Lu-DOTA-TLX591)

Not yet recruiting
  • Prostate Cancer
  • 177Lu-DOTA-TLX591
  • St Leonards, New South Wales, Australia
  • +1 more
Jul 18, 2022

Prostatic Tumors, Castration-Resistant Trial in Darlinghurst, Pretoria (225^Ac-PSMA-617, 68^Ga-PSMA-11)

Recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • 225^Ac-PSMA-617
  • 68^Ga-PSMA-11
  • Darlinghurst, Australia
  • +1 more
Nov 23, 2022

Prostate Cancer Trial in Amsterdam, Groningen, Nijmegen (177Lu-PSMA-617)

Recruiting
  • Prostate Cancer
  • Amsterdam, Netherlands
  • +3 more
Oct 17, 2021

Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma Trial in San Francisco

Active, not recruiting
  • Castration Levels of Testosterone
  • +6 more
  • Lutetium Lu 177-PSMA-617
  • Pembrolizumab
  • San Francisco, California
    University of California, San Francisco
Apr 11, 2022

Metastatic Castration-resistant Prostate Cancer Trial in Oslo (212Pb-NG001)

Not yet recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Oslo, Norway
    Oslo University Hospital
Feb 13, 2023

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer Trial (Image Guided Biopsy)

Withdrawn
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Image Guided Biopsy
  • (no location specified)
Jul 22, 2020

Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2

Recruiting
  • Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
  • Duarte, California
  • +12 more
Jul 6, 2022

Metastatic Castration-resistant Prostate Cancer Trial (225Ac-PSMA)

Unknown status
  • Metastatic Castration-resistant Prostate Cancer
  • (no location specified)
Jan 8, 2020

Metastatic Castration-resistant Prostate Cancer Trial in Nanjing (177 Lu-PSMA-I&T)

Unknown status
  • Metastatic Castration-resistant Prostate Cancer
  • 177 Lu-PSMA-I&T
  • Nanjing, Jiangsu, China
    Nanjing First Hospital
Dec 4, 2019

Refractory Solid Tumor Trial in Xiamen (177Lu-DOTA-EB-FAPI radionuclide therapy)

Recruiting
  • Refractory Solid Tumor
  • 177Lu-DOTA-EB-FAPI radionuclide therapy
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 26, 2023

Prostatic Tumors, Castration-Resistant Trial in Brisbane ([212Pb]Pb-ADVC001)

Not yet recruiting
  • Prostatic Neoplasms
  • Castration-Resistant
  • Brisbane, Queensland, Australia
    Royal Brisbane & Women's Hospital
Feb 9, 2023

Refractory Thyroid Gland Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Refractory Thyroid Gland Follicular Carcinoma

Recruiting
  • Refractory Thyroid Gland Carcinoma
  • +3 more
  • 177Lu-DOTA-EB-FAPI 1 radionuclide therapy
  • +2 more
  • Xiamen, China
    The First Affiliated Hospital of Xiamen University
Nov 3, 2022

Prostate Cancer Trial in London (177Lu-PNT2002, High Dose Radiation)

Recruiting
  • Prostate Cancer
  • London, Ontario, Canada
    London Health Sciences Centre
Nov 22, 2022

Prostate Cancer Trial in Beijing (2.0 GBq of 177Lu-EB-PSMA)

Recruiting
  • Prostate Cancer
  • 2.0 GBq of 177Lu-EB-PSMA
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Jul 13, 2022

Pancreatic Ductal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Glioblastoma Multiforme Trial (68Ga-FF58, 177Lu-FF58)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +2 more
  • (no location specified)
Jul 28, 2023